Cohance Lifesciences Reports Audited FY26 Financial Results and Approves KMP Revisions
Cohance Lifesciences announced audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Revenue from operations for FY26 stood at ₹2,030.50 crore (standalone) and ₹2,268.55 crore (consolidated). Net profit after tax for FY26 was ₹228.71 crore (standalone) and ₹150.12 crore (consolidated). The company also revised its authorized Key Managerial Personnel for disclosures.
The announcement includes the audited financial results for the full year and quarter, which are material information for investors. Additionally, changes in authorized personnel for disclosures are a governance-related update.
The announcement primarily reports financial results and routine corporate governance updates. While the financial results are presented, there are no significant positive or negative surprises that would strongly sway the sentiment.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced the outcome of its Board Meeting held on May 12, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Accompanying documents include the detailed financial results, audit reports with unmodified opinions, a press release, and an investor presentation.
Furthermore, the Company approved revisions to the authorized Key Managerial Personnel for determining materiality and making disclosures, as per Regulation 30(5) of SEBI Listing Regulations. The "Policy for Determining Material Event or Information" was amended effective May 12, 2026, with Mr. Umang Vohra as Chairman, Mr. Himanshu Agarwal as Whole-time Director and Chief Financial Officer, and Mr. Sisir K. Mishra as Company Secretary & Compliance Officer.
The Board meeting commenced at 2:30 pm IST and concluded at 4:30 pm IST. The financial statements reflect restated figures due to the amalgamation of the erstwhile fellow subsidiary, Cohance Lifesciences Limited, effective May 1, 2025. The company reported revenue from operations for the year ended March 31, 2026, at ₹2,030.50 crore (standalone) and ₹2,268.55 crore (consolidated). For the same period, net profit after tax was ₹228.71 crore (standalone) and ₹150.12 crore (consolidated). The company also noted an incremental financial impact of ₹4.86 crore due to the implementation of new labor codes.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.